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Introduction: The prevalence of nonhealing wounds is predicted to increase due to the growing aging population.
Despite the use of novel skin substitutes and wound dressings, poorly vascularized wound niches impair wound
repair. Mesenchymal stem cells (MSCs) have been reported to provide paracrine signals to promote wound healing,
but the effect of human Wharton’s jelly-derived MSCs (WJ-MSCs) has not yet been described in human normal skin.
The aim of this study is to examine the effects of human WJ-MSC paracrine signaling on normal skin fibroblasts
in vitro, and in an in vivo preclinical model.
Methods: Human WJ-MSCs and normal skin fibroblasts were isolated from donated umbilical cords and normal
adult human skin. Fibroblasts were treated with WJ-MSC-conditioned medium (WJ-MSC-CM) or nonconditioned
medium.
Results: Expression of genes involved in re-epithelialization (transforming growth factor-β2), neovascularization
(hypoxia-inducible factor-1α) and fibroproliferation (plasminogen activator inhibitor-1) was upregulated in WJ-MSC-
CM-treated fibroblasts (P≤ 0.05). WJ-MSC-CM enhanced normal skin fibroblast proliferation (P≤ 0.001) and migration
(P≤ 0.05), and promoted wound healing in an excisional full-thickness skin murine model.
Conclusions: Under our experimental conditions, WJ-MSCs enhanced skin wound healing in an in vivo mouse model.Introduction
Nonhealing or chronic wounds represent an increasingly
prevalent and costly public health issue. As a consequence
of longer lifespans due to improvements in acute care, the
number of patients who suffer diabetes and other chronic
aging-related diseases is growing considerably. There is a
link with aging-associated diseases and wound healing im-
pairment [1]. On the other hand, other wound healing
challenges also arise at any age because of accidents, burns
and other traumatic injuries.
Mesenchymal stem cells (MSCs) appear to emerge as
a promising wound healing therapy. Paracrine signaling,
such as the release of factors that promote angiogenesis,
immunomodulation and recruitment of endogenous* Correspondence: marc.jeschke@sunnybrook.ca
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unless otherwise stated.tissue stem/progenitor cells, as well as differentiation,
have been described as possible mechanisms underlying
the positive wound healing effects of MSCs [2,3]. From
the different available sources of MSCs, the umbilical
cord represents a cost-effective, productive, feasible, ac-
cepted, and universal source to isolate MSCs, and is
considered advantageous compared with bone marrow-
derived mesenchymal stem cells (BM-MSCs) and
adipose-derived MSCs for some researchers [4]. Previous
studies with umbilical cord Wharton’s jelly-derived mes-
enchymal stem cells (WJ-MSCs) have demonstrated
that they represent a high-yield source of young, nontu-
morigenic and immunomodulatory cells that may be allo-
transplanted to regenerate liver, heart, bone, cartilage, fat,
pancreas, neural, vascular/endothelial and skin compo-
nents [5]. WJ-MSCs isolated from goats have been
demonstrated to accelerate wound closure in animals
from the same species, while minimizing granulation tis-
sue and inflammation [6]. Human WJ-MSCs decreased. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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shown to be able to differentiate into sweat gland-like cells
and may therefore promote skin regeneration [10]. WJ-
MSCs secrete proangiogenic and wound healing promot-
ing factors, such as transforming growth factor beta
(TGF-β), vascular endothelial growth factor (VEGF),
platelet-derived growth factor, insulin-like growth
factor-I, interleukin (IL)-6 and IL-8, among others
[11]. Paracrine effects appear to be responsible for
the wound healing promoting effects of WJ-MSCs, at
least in mice [12]. However, to date, there are no re-
ports regarding the use of human WJ-MSCs in hu-
man skin wounds.
The novelty of this study lies in the use of a promising
stem cell type, the WJ-MSC, which has yet not been
studied in the context of human skin, and investigating
the in vitro effect on human skin fibroblasts, as a means
to develop a new therapeutic strategy to aid in wound
healing. Specifically, the aim of this study is to analyze the
wound healing effects of human WJ-MSC paracrine sig-
naling on human normal skin fibroblasts in vitro, and to
examine the application of WJ-MSC conditioned medium
(CM) into an in vivo mouse wound healing model.
Materials and methods
Tissue sources
Normal skin was obtained from healthy donors undergoing
plastic surgery procedures (mostly dermolipectomies), both
men and women, excluding pregnant females. Umbilical
cords were obtained from pregnant women after planned
delivery through caesarian section. Tissues were obtained at
the Department of Plastic Surgery and the Department of
Obstetrics and Gynecology, respectively, at Sunnybrook
Health Sciences Centre, University of Toronto, Toronto,
Ontario, Canada. Tissue specimens were collected following
the Declaration of Helsinki Principles, following Toronto
Academic Health Sciences Network (TAHSN) and Univer-
sity of Toronto-affiliated Sunnybrook Research Institute
and Sunnybrook Health Sciences Centre Institutional Ethics
Review Board approval, and after getting patient signed in-
formed consent.
Cell culture
Primary human normal skin fibroblasts and human WJ-
MSCs were obtained from skin tissue samples and um-
bilical cords, respectively. Skin was dissected to remove
any underlying fat, cut into small explant pieces of 2 to
4 mm, and cultured in small dishes. WJ-MSCs were iso-
lated from umbilical cords by gentle dissection of previ-
ous sectioned small cord pieces, discarding the outer or
epithelial layer, according to earlier described methods
[13]. Explants and MSCs were further subcultured in
Petri dishes at a density of 3,200 cells/cm2 for 7 days be-
fore further passaging. When fibroblasts and/or WJ-MSCsreached 70% confluence, usually within 1 week, they were
trypsinized with 0.05% trypsin/0.025% ethylenediamine
tetraacetic acid v/v in preparation for subculture. Fibro-
blasts were subcultured in 75 cm2 tissue culture flasks at a
density of 4,500 cells/cm2. Tissue culture plasticware were
purchased from BD Falcon™ (Bedford, MA, USA), and all
tissue culture media and supplements were obtained from
Wisent Inc. (St-Jean-Baptiste, QC, Canada), unless other-
wise stated. Fibroblast culture medium consisted of high-
glucose Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) and 1%
antibiotic–antimycotic solution. WJ-MSC culture medium
consisted of CMRL (Gibco, Carlsbad, CA, USA) with 10%
FBS, 2% antibiotic–antimycotic solution and 1% L-glutam-
ine. Media were changed every 48 hours. Collected tissues
and cells were cultured at 37°C in a humidified atmos-
phere with 5% carbon dioxide.
Characterization of human Wharton's jelly-derived MSCs
The cells isolated from the Wharton’s jelly of the umbil-
ical cord were examined to confirm their MSC charac-
teristics. Flow cytometry for MSC cell surface markers
(CD90+, CD73+, CD105+, CD45–, CD14–, CD34–, CD19–
and HLA-DR–) was performed (Additional file 1). Cells
were differentiated into the three main mesenchymal
lineages – adipogenic, osteogenic and chondrogenic
(Additional file 1). For adipogenic differentiation, cells were
seeded at a density of 3,000 cells/cm2 in 24-well plates
(BD) with low-glucose DMEM (Wisent Inc., St-Jean-
Baptiste, QC, Canada) medium supplemented with 10%
FBS, 1% antibiotic–antimycotic solution, 1 mM 3-isobutyl-
1-methylxanthine (Sigma-Aldrich, Saint Louis, MO, USA),
10 μg/ml insulin (SAFC, Saint Louis, MO, USA), 60 μM
indomethacin (Sigma-Aldrich), and 1 μM dexamethasone
(Sigma-Aldrich). Cultures of cells in low-glucose DMEM
medium supplemented with 10% FBS served as a negative
control. Lipid accumulation was identified by oil red O
staining: 0.3 g oil red O (Sigma-Aldrich) dissolved in
100 ml isopropanol (Sigma-Aldrich), diluted to 60% with
distilled water.
For osteogenic differentiation, cells were also seeded
at a density of 3,000 cells/cm2 in 24-well plates with
low-glucose DMEM supplemented with 10% FBS, 1%
antibiotic–antimycotic solution, 0.05 mM ascorbic acid-2-
phosphate (Wako Pure Chemicals Industry Ltd, Osaka,
Japan), 10 mM β-glycerophosphate (Sigma-Aldrich), and
100 nM dexamethasone (Sigma-Aldrich). Alizarin red
staining (Sigma-Aldrich) was used to identify osteogenic
cells (2 g alizarin red dissolved in 100 ml distilled water).
For chondrogenic differentiation, cells were seeded in
15 ml polypropylene tubes (2 × 105 cells per tube; BD
Falcon, Bedford, MA, USA) with low-glucose DMEM
supplemented with 10% FBS, 1% antibiotic–antimyco-
tic solution, 1 mM sodium pyruvate (Sigma-Aldrich),
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Industry Ltd), 1% insulin–transferrin–selenium (Cellgro,
Manassas, VA, USA), 100 nM dexamethasone (Sigma-
Aldrich), and 10 ng/ml TGF-β3 (Shenandoah Biotech-
nology, Inc., Warwick, PA, USA). Chondrocyte pellets
were identified with Safranin O staining: 0.1 g Safranin O
(Sigma-Aldrich), dissolved in 100 ml distilled water.
Human normal fibroblasts and Wharton's jelly-derived
MSC one-way paracrine signaling indirect co-culture
First, primary human fibroblasts were seeded into six-
well plates (Grenier-Bio-One Cellstar, Frieckenhausen,
Germany) at a density of 22,000 cells/cm2 with DMEM.
To design a one-way indirect or paracrine co-culture
system between human normal skin fibroblasts and WJ-
MSCs, the WJ-MSCs were separately seeded at the same
cell density in the upper three wells of a six-well plate
with CMRL media; the lower three wells of the same
six-well plate were filled with CMRL medium alone.
When refreshing the media (once every other day), the
six-well plate containing the fibroblasts was filled with
the medium from the WJ-MSC six-well plate: the three
upper wells (treatment wells) with the WJ-MSC-CM,
and the three lower wells (control wells) with the CMRL
media alone. On day 5 of culture, the amount of FBS in
the medium was reduced from 10 to 2%, to avoid TGF-
β1 false measurements. On day 7, total RNA extraction
was started for further gene expression studies. Experi-
ments were performed with low-passage cells (less than
passage 5) and in triplicate (unless otherwise stated), on
one set of cells from different patients.
RNA isolation and real-time quantitative polymerase
chain reaction
For RNA isolation, cells were lysed using TRIzol reagent
(Invitrogen, Carlsbad, CA, USA), and the RNeasy Micro-
Kit was used (Qiagen, Inc., Valencia, CA, USA) accord-
ing to the manufacturer’s instructions. The total RNA
yield was determined using a NanoDrop-2000 spect-
rophotometer (ThermoScientific, Waltham, MA, USA).
cDNA was synthesized in a thermocycler (AB Applied
Biosystems, Foster City, CA, USA), after mixing 10 μg
RNA and a master mix prepared with the high-capacity
cDNA synthesis reverse transcription kit (AB Applied
Biosystems). Real-time polymerase chain reaction
(PCR) was conducted using SYBR® Green PCR Master
Mix (Applied Biosystems) to relatively quantify the
mRNA transcript products of the following genes of
interest: TGF-β1, TGF-β2, TGF-β3, plasminogen activa-
tor inhibitor-1, connective tissue growth factor, fibroblast
growth factor-2, hypoxia-inducible factor-1α, VEGF,
collagen I, collagen III and decorin. 18S was used as
housekeeping gene. The primer sequences of the above
genes used are listed in Additional file 2. Amplificationand analysis of cDNA fragments were carried out
using the StepOnePlus RT-PCR System (AB Applied
Biosystems).
Relative gene expression was measured as the cycle
threshold and was normalized with individual house-
keeping gene control cycle threshold values. Quantitative
PCR was loaded in duplicate, and cycle threshold values
from triplicates of the same treatment group sample
were averaged. The ΔΔCt method was used to report
quantitative PCR results.
Proliferation assay: Ki67 antigen staining
Normal skin fibroblasts and WJ-MSCs were seeded in
different eight-chamber culture slides at a cell density of
715 cells/cm2 and cultured for 7 days, following methods
described above. Briefly, the media from the wells con-
taining WJ-MSC (WJ-MSC-CM) were used to fill the
wells from the normal skin fibroblasts from the treated
group every other day, whereas wells of the control group
were filled with WJ-MSC nonconditioned media.
Immunofluorescence
Cells were washed with phosphate-buffered saline (PBS)
and fixed for 15 minutes in 4% paraformaldehyde (Alfa
Aesar, Karlsruhe, Germany). Fixed cells were washed in
PBS and permeabilized for 10 minutes with PBS/0.5%
Triton X-100 solution. After another washing step, cells
were blocked for 30 minutes with 1% bovine serum al-
bumin in PBS/0.5% Triton X-100. A monoclonal mouse
anti-human Ki67 (1:100, clone MIB-1; Dako, Markham,
ON, Canada) primary antibody was added and incubated
overnight at 4°C. After washing with PBS, the secondary
antibody was added in 1% bovine serum albumin in PBS/
0.5% Triton X-100 and incubated for 1 hour at room tem-
perature in the dark (Alexa Fluor 488 donkey anti-
mouse, 1:500; Life Technologies, Eugene, OR, USA).
After three final washes with PBS, slides were mounted
with Vectashield mounting medium with 4′,6-diamidino-
2-phenylindole (DAPI; Vector Laboratories, Burlingame,
CA, USA). Cells were examined and photographed using
an Apotome Axiovert fluorescent imaging system at 10×
magnification (Zeiss, Oberkochen, Germany). Three im-
ages were taken per well and two wells were imaged per
treatment. Quantification was performed by counting the
number of Ki67-positive cells in the high-power field as
well as the total number of DAPI-positive nuclei. Data are
presented as means with 95% confidence intervals of
duplicate measurements for three different normal skin
samples.
Terminal transferase TdT-mediated dUTP biotin
end-labeling apoptosis assay
Normal fibroblasts cultured with WJ-MSC-CM and with
nonconditioned medium were seeded into eight-chamber
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half a week. The terminal transferase TdT-mediated dUTP
biotin end-labeling apoptosis kit (Promega, Fitchburg, WI,
USA) was used as per the manufacturer’s instructions.
Briefly, cells were fixed in 4% paraformaldehyde for
25 minutes at 4°C and washed with PBS. They were
permeabilized with 0.25% Triton X-100 in PBS for 5 mi-
nutes, and then washed with PBS. Cells were incubated
with equilibration buffer for 10 minutes, followed by la-
beling with terminal deoxynucleotidyl transferase reac-
tion mix (10% nucleotide mix, 0.02% rTdT enzyme in
equilibration buffer) for 1 hour at 37°C in humidified
chamber. Cells were immersed in 2× SSC for 15 minutes
to stop the reaction, followed by washes with PBS. Slides
were mounted with Vectashield mounting medium with
DAPI (H-1200; Vector Laboratories). Images were taken
on an Apotome Axiovert fluorescent imaging system at
10× magnification (Zeiss); three images were taken per
well. Quantification was performed by counting the num-
ber of terminal transferase TdT-mediated dUTP biotin
end-labeling-positive and DAPI-positive nuclei, or apop-
totic and alive cells, respectively.
Cell migration study: scratch wound assay
Normal skin fibroblasts were seeded in four-chamber
culture slides at a cell density of 1,000 cells/cm2, with
WJ-MSC-CM (or non-conditioned medium as control)
for 48 hours. Two scratches were performed with a
200 μl pipette tip. After 24 hours, cells were fixed with
4% paraformaldehyde. The staining protocol followed
the same procedure as the aforementioned proliferation
assay. Briefly, cells were incubated with phalloidin anti-
body conjugated to fluorescein isothiocyanate (1:30;
Invitrogen, Eugene, OR, USA) in blocking solution for
1 hour. Cells were washed three times with PBS and
mounted with Vectashield mounting medium with DAPI.
Images were taken on laser scanning META 510 confocal
microscope (Zeiss) with 5× magnification. Three images
were taken per scratch. Quantification was performed
using ImageJ software (National Institutes of Health,
Bethesda, MD, USA). A set area with a height of 0.5 mm
and a width spanning the high-power field was placed in
the center of the scratch, and the cells within this area
were counted as the cells in scratch zone.
In vivo wound healing model
Eight BALB/c mice (13 weeks old, male, body weight 28
to 34 g) were obtained from Jackson Laboratory under
the guidelines of the Sunnybrook Research Institute and
Sunnybrook Health Sciences Animal Policy and Welfare
Committee of the University of Toronto. Animal proce-
dures were reviewed and approved by Sunnybrook Re-
search Institute and Sunnybrook Health Sciences Centre
at University of Toronto animal care and use committee.Animals were anesthetized and back cutaneous hair was
removed by electrical shaving under anesthesia as stated
in the Animal Protocol. Two pairs of 4 mm diameter
full-thickness skin excisional wounds were created on
each side of the midline. The animals were randomly di-
vided into two groups: treatment (WJ-MSC-CM and
Matrigel; BD Biosciences, San Jose, CA, USA) and sham
(nonconditioned medium and Matrigel). Matrigel was of
high concentration and was applied dropwise in liquid
form and then allowed to gel. Each wound topically re-
ceived 100 μl treatment or sham mix.
Wound analysis
Wound measurements were taken and wound closure
was examined in a timely manner on days 1, 3 and 7.
Wounds with a complete re-epithelialization were con-
sidered healed wounds.
Mice were sacrificed at day 7, when skin biopsies in-
cluding the wound/scar and 2 mm of satellite skin were
harvested for further histologic analysis. Twenty-four
hours before sacking, animals received an intraperitoneal
injection of bromodeoxyuridine (BrdU) (Calbiochem, San
Diego, CA, USA).
Histologic examination
Tissue specimens were fixed in 10% buffered formalin
overnight at room temperature, preserved in 70% etha-
nol and embedded in paraffin. Specimens were cut into
5 μm sections. Tissue specimens were cut simultaneous-
ly at different sites, the center or midline and both sides,
eliciting a cross-section through the whole wound and
satellite area. A serial section of the scar or healing wound
was performed. The largest wound diameter or central
wound section was stained for trichrome staining. Tri-
chrome reagents were from EMS (Hatfield, PA, USA) un-
less otherwise stated. Briefly, paraffin-embedded slides
were deparaffinized with citrosol, followed by rehydration
through 100%, 95%, 70% and 50% ethanol to water. Slides
were placed in Bouin’s solution (26367–01; EMS, Hatfield,
PA, USA) overnight at room temperature and washed
next. Hematoxylin stain (HHS16; Sigma, Saint Louis,
MO, USA) and Biebrich scarlet-acid fuchsin solution
were applied sequentially for 10 minutes. Washes were
performed after each stain addition. Slides were
differentiated in phosphomolybdic–tungstic acid for
15 minutes, and were transferred to aniline blue for
5 minutes. They were next rinsed and differentiated
in 1% acetic acid for 2 minutes. Slides were dehydrated
through 95% ethanol and absolute ethanol followed by
clearing in citrosol. Slides were mounted with SHUR/
Mount xylene-based liquid mounting media (Triangle
Biomedical Sciences, Durham, NC, USA). Images were ac-
quired using a Zeiss Axiovert 200 light microscope at 10×
and 40× magnification. Quantification was carried out
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satellite area.
For immunohistochemistry staining, paraffin-embedded
skin tissue slides were deparaffinized with xylene followed
by rehydration. Antigen decloaker (1×; Biocare Medical,
Concord, CA, USA) was added to the slides in a preheated
decloaking chamber for 4 minutes at 110°C. For BrdU
staining, samples were denatured with 1.5 N HCl for
30 minutes at 37°C and neutralized with 0.1 M borate
buffered twice for 5 minutes. Samples were blocked with
3% H2O2 for 10 minutes, and then washed with washing
buffer (0.05 M Tris–HCl, 0.15 M NaCl, 0.05% Tween 20
in deionized water). The primary antibody (mouse mo-
noclonal anti-BrdU, 1:200; Cell Signaling, Beverly, MA,
USA) was diluted in PBS and incubated at room tempera-
ture for 1 hour. Slides were then incubated for 15 minutes
first with MACH3 mouse probe (Biocare Medical), and
secondly with MACH3 rabbit or mouse horseradish per-
oxidase polymer, with before and after washes. The beta-
zoid diaminobenzidine chromogen kit (Biocare Medical)
was mixed and added for 5 minutes or until brown stain
was noticeable. The reaction was terminated with running
water. Nuclear staining was carried out with hematoxylin
for 30 seconds, followed by differentiation with three dips
in 1.5% acid alcohol and bluing in 0.1% sodium bicar-
bonate for 10 seconds. Sections were dehydrated through
95% and absolute ethanol to citrosol and mounted with
SHUR/Mount as described previously. Images were ac-
quired using a Zeiss Axiovert 200 light microscope at 10×
magnification to image the whole section followed by 40×
magnification to further focus on the wound margins and
the wound center. The higher magnification images of
BrdU staining were quantified by counting using ImageJ
software, and normalized to the number of cells in the
high-power field.
Statistical analysis
The statistical comparisons between the groups were per-
formed using an unpaired Student’s t test with GraphPad
Prism software (GraphPad, LaJolla, CA, USA). Two-tailed
P ≤ 0.05 was considered significant. Data were graphically
expressed as the mean of the target group ± the standard
error of the mean or 95% confidence interval.
Results
Wharton's jelly-derived MSCs enhance the expression of
wound healing genes by paracrine signaling
Human WJ-MSCs upregulated the mRNA transcript ex-
pression of TGF-β2, hypoxia-inducible factor-1α, and plas-
minogen activator inhibitor-1 genes (P ≤ 0.05) in normal
skin fibroblasts in our culture conditions. Other genes in-
volved in re-epithelialization, neovascularization and/or
remodeling – including VEGF, fibroblast growth factor-2,
connective tissue growth factor, collagen I and collagenIII – were not changed. Decorin and TGF-β3 also re-
mained unaffected (Figure 1).
Normal skin fibroblasts proliferate faster when treated
with Wharton's jelly-derived MSC conditioned medium
In our culture conditions, WJ-MSC-CM accelerated nor-
mal skin fibroblasts proliferation (P ≤ 0.001), as measured
by a Ki67 proliferation assay (Figure 2A,B,C).
Wharton's jelly-derived MSC conditioned medium does
not induce apoptosis in normal skin fibroblasts
We did not find any significant modulation in the num-
ber of apoptotic fibroblasts treated with WJ-MSC-CM
using a terminal transferase TdT-mediated dUTP biotin
end-labeling assay, suggesting that WJ-MSC-CM does
not appear to affect normal skin fibroblast apoptosis
under our culture conditions (Figure 2D). An increased
apoptosis rate could imply a delayed wound healing pro-
cess, whereas a much decreased apoptosis rate could im-
ply enhanced risk of keloid scars.
Wharton's jelly-derived MSC conditioned medium
promotes normal skin fibroblast migration and
wound closure
To further examine whether the enhanced proliferation
of fibroblasts treated with WJ-MSC-CM may also promote
wound closure, a wound scratch assay was performed.
In our culture conditions, WJ-MSC-CM-treated nor-
mal skin fibroblasts coapted wound borders faster than
normal skin fibroblasts from the control group (that is,
those treated with WJ-MSC nonconditioned medium),
suggesting that WJ-MSC-CM enhanced fibroblast mi-
gration. This observation is important, because cell mi-
gration is an essential step during wound healing. This
fact highlights that healing promotion is partly due to
faster migration, and consequently acceleration of wound
closure, in human normal skin fibroblasts (Figure 3A,B).
Wharton's jelly-derived MSC conditioned medium pro-
motes wound healing and repair in a mouse model
We next examined whether the in vitro wound healing
promoting observed effects with WJ-MSC-CM might be
translated into an in vivo wound healing model. BALB-c
mice with WJ-MSC-CM-treated wounds showed enhanced
wound healing rates compared with the control mice
(P ≤ 0.05) (Figure 4A,B, quantified in 4C). Increased
and complete re-epithelialization, higher cellularity in
newly formed granulation tissue, and less random and
more organized extracellular matrix were observed in the
WJ-MSC-CM-treated wounds, suggesting that WJ-MSC-
CM promoted wound healing and repair in vivo in mice.
To delineate the pro-proliferative effect of WJ-MSC-
CM in vivo, one dose of BrdU was injected intraperitone-
ally. Both a higher number of cells and a higher amount of
Figure 1 Upregulation of wound healing genes by human Wharton's jelly-derived mesenchymal stem cell conditioned medium in
human normal skin fibroblasts. (A-L) mRNA transcript expression relative to 18S after 7 days of culture of human normal skin fibroblasts with
Wharton's jelly-derived mesenchymal stem cell conditioned medium (WJ-MSC-CM; treatment group) or nonconditioned medium (control group)
from five different patients (but four patients for FGF-2 and three patients for collagen I, collagen III and decorin). Overall, WJ-MSC-CM enhanced
a wound healing promoting phenotype in human normal skin fibroblasts in our culture conditions. *P ≤ 0.05. COL, collagen; CTGF, connective
tissue growth factor; FGF-2, fibroblast growth factor-2; HIF-1α, hypoxia-inducible factor-1α; PAI-1, plasminogen activator inhibitor-1;
TGF-β, transforming growth factor beta; VEGF, vascular endothelial growth factor.
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wounds (P ≤ 0.05 and P ≤ 0.01, respectively) (Figure 5E,F).
A microscopic wound cross-section showed a highernumber of positive proliferating nuclei (black arrows,
BrdU-positive cells) (P ≤ 0.01) in the WJ-MSC-CM-treated
wounds (Figure 5D) compared with the control wounds
Figure 2 (See legend on next page.)
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Figure 2 Wharton's jelly-derived mesenchymal stem cell conditioned medium increases normal skin fibroblast proliferation, but does
not affect apoptosis. Cell proliferation was examined using Ki67 staining. (A) Wharton's jelly-derived mesenchymal stem cell conditioned
medium (WJ-MSC-CM)-treated normal fibroblasts showed enhanced proliferative rates compared with the control group (quantified in (B)). (C)
Terminal transferase TdT-mediated dUTP biotin end-labeling (TUNEL) staining of WJ-MSC-CM-treated human normal skin fibroblasts versus control
(non-WJ-MSC-CM-treated) normal skin fibroblasts showed no significant difference in induction of apoptosis (quantified in (E)). Note that the
total number of viable cells was significantly higher in the WJ-MSC-CM-treated cells compared with the non-WJ-MSC-CM-treated cells (D). n = 3
samples per group. *P ≤ 0.05, ***P ≤ 0.001. DAPI, 4′,6-diamidino-2-phenylindole.
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remodeling and overall wound repair. Higher magnifica-
tion images corresponding to the aforementioned detailed
micrographs of both control and treated wounds were
shown in Figure 5A and 5B, respectively (Additional file 3
supports and complements Figure 5).
Discussion
The results of this study suggest that WJ-MSCs enhance
wound healing and normal wound repair by paracrineFigure 3 Wharton's jelly-derived mesenchymal stem cell conditioned
assay was performed to examine migration properties of Wharton's jelly-deriv
and untreated normal skin fibroblasts. The treated group showed significantly
control group. *P≤ 0.05.signaling mechanisms. Under our culture conditions, hu-
man WJ-MSC-CM upregulated the gene expression of
wound healing factors in human normal skin fibroblasts,
and promoted fibroblast proliferation and migration to co-
apt wound borders in vitro. Accordingly, WJ-MSC-CM
accelerated the re-epithelialization rate and promoted
wound repair in vivo in a full-thickness excisional mouse
wound healing model.
Cutaneous wound repair is a complex orchestrated
process that is activated upon injury and includes themedium accelerates wound closure in vitro. (A), (B) Scratch wound
ed mesenchymal stem cell conditioned medium (WJ-MSC-CM)-treated
enhanced migration rates and coapted wound borders faster than the
Figure 4 Wharton's jelly-derived mesenchymal stem cell conditioned medium enhances wound healing in an in vivo mouse model. A
murine wound healing model was used, and animals were wounded and treated as described previously. Images corresponded to histological
sections of wounds and the satellite donut area (10×) from BALB-c mice, after 1 week of full-thickness excisional skin wounding and reconstruction
with Wharton's jelly-derived mesenchymal stem cell conditioned medium (WJ-MSC-CM) and vehicle (Matrigel; BD Biosciences, San Jose, CA, USA) (B),
or vehicle alone (A). Photomicrographs were taken after Masson’s Trichrome staining. BALB-c mice WJ-MSC-CM-treated wounds showed enhanced
wound healing rates compared to the control mice (P≤ 0.05) (C). *P≤ 0.05. Error bars represent the 95% confidence interval.
Arno et al. Stem Cell Research & Therapy 2014, 5:28 Page 9 of 13
http://stemcellres.com/content/5/1/28multicellular overlapping and coordinated phases of
inflammation, angiogenesis and formation of granulation
tissue, re-epithelialization, and fibroproliferation or matrix
formation and remodeling [14,15]. Decreased proinflam-
matory cytokines, compromised neovascularization and/
or impairment in leukocyte recruitment might disturb and
delay wound healing [16]. Despite the current use and
availability of a wide array of wound dressings, ointments
and devices, wound healing still remains a clinical chal-
lenge, especially in older patients, diabetic patients, heavy
smokers or burned patients [17–21]. There is therefore a
need for new strategies to promote or at least coadjuvantly
help in wound healing and repair.
Skin MSCs have been reported to populate the normal
skin niche, remain quiescent and become active after in-
jury, aiding in wound closure [14,15]. MSC paracrine sig-
naling has been suggested to be the main underlying
mechanism for MSCs enhanced wound repair effects
[2,22,23]. BM-MSCs have been reported to promote
wound healing, but their isolation requires an invasive and
artificial method [24,25]. Harvesting adipose-derived stemcells also requires a surgical procedure. Subsequently, we
focused on a more advantageous MSC source, the umbil-
ical cord-derived Wharton’s jelly [5,25,26]. The harvest of
WJ-MSCs is not painful or invasive, as the cells are isolated
naturally with no extra surgery and are dissected from dis-
carded umbilical cords after birth. Indeed, caprine WJ-
MSCs have already been shown to promote wound repair
with minimal scarring [6], but to our knowledge there are
no reports of human WJ-MSC treatment on human skin
wounds. WJ-MSCs represent a very efficient stem cell
source with reported immunoprivileged, anticancer and
antifibrotic characteristics in animal models [25–28]. Due
to their reported immunoprivileged properties and univer-
sal and ever-lasting availability [5], WJ-MSC allotransplan-
tion as an off-the-shelf therapy may represent an
appropriate treatment strategy in the already compromised
patients who suffer of recalcitrant cutaneous wounds [14].
This study therefore aimed to examine the effects of
human WJ-MSC paracrine signaling on human normal
skin fibroblasts. In our culture conditions, human WJ-
MSCs enhanced the expression of some wound healing
Figure 5 (See legend on next page.)
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Figure 5 Wharton's jelly-derived mesenchymal stem cell conditioned medium promotes cell proliferation in an in vivo mouse wound
healing model. A BALB-c mouse wound healing model was used and animals were wounded and treated as described previously. Animals
received one dose of bromodeoxyuridine (BrdU) intraperitoneally 24 hours before harvesting of wounds. Four animals were included in each
group, and four wounds were performed per animal (total of 16 wounds in each group). Cutaneous tissue specimens were stained for BrdU in
both groups, control (A) and treatment (B). Enhanced magnification (40×) of the above microscopic images were included for nonconditioned
medium-treated (C) and Wharton's jelly-derived mesenchymal stem cell conditioned medium (WJ-MSC-CM)-treated normal skin fibroblasts (D) to
examine in further detail the increase in cell number or stained nuclei (black arrows, BrdU-positive cells) in the WJ-MSC-CM-treated wounds,
compared with controls. This denoted that WJ-MSC-CM stimulated cell proliferation in vivo (E, F). Together, these results suggest that WJ-MSC
promoted wound healing and repair by one-way paracrine signaling in an in vivo preclinical model. *P ≤ 0.05, **P ≤ 0.01. Error bars represent the
95% confidence interval. Arrows, BrdU-positive nuclei; arrowheads, BrdU-negative nuclei. HPF, high-power field.
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cularization and fibroproliferation inducing genes, in hu-
man normal skin fibroblasts. Besides altering skin
fibroblast gene expression, MSC signaling has also been
shown to positively regulate cell survival, proliferation
and migration [23,29]. Under our culture conditions, al-
though apoptotic changes were not found in skin fibro-
blasts treated with WJ-MSC-CM, significantly enhanced
proliferation and migration were observed. This is import-
ant, as cellular dynamics and cell migration constitute an
essential step during cutaneous healing. WJ-MSC-CM ac-
celerated wound closure both in vitro and in an in vivo
mouse wound healing model, suggesting that human WJ-
MSC-CM may promote wound repair.
Other researchers have also reported enhanced wound
healing rates in mouse models with other human MSC
sources, such as BM-MSCs [23,30] and umbilical cord
blood-derived MSCs [31]. Blood of the umbilical cord
has been reported to yield fewer MSCs than the cord it-
self [31], however, and Wharton’s jelly may therefore
emerge as a more appropriate stem cell source. To the
best of our knowledge, no published studies regarding
the use of human WJ-MSCs in human wounds have
been reported, so this work is novel, and could prompt
us to test whether the same results would be encoun-
tered first in a more appropriate but more costly experi-
mental model, such as the red duroc pig. Secondly, if the
results appeared to be promising, the next step would be
to translate them into phase I or phase II clinical trials
for further evaluation and development. Indeed, pilot
clinical studies have so far indicated that MSCs in ge-
neral are safe in vivo, and they currently represent the
most widely used stem cells in the clinical setting [26].
Accordingly, in the particular case of WJ-MSCs, 15 dia-
betic patients received systemically WJ-MSCs with no
documented relevant safety concerns [32]. Furthermore,
many MSC clinical applications to manage intestinal fis-
tulae, acute artery ischemic disease in diabetic patients,
and periodontal defects have been reported, among others
[26]. Anecdotally, one case report about autologous BM-
MSCs used to help to heal a scapular recalcitrant wound
in a Russian burned patient has also been published [33],
but no reports regarding the use of WJ-MSCs have yetbeen reported. Although WJ-MSCs secrete a more angio-
genic secretome in comparison with BM-MSCs [34], the
isolation of WJ-MSCs is more efficient, and WJ-MSCs
have a higher capacity of proliferation and are less senes-
cent than adipose-derived stem cells [35], proper studies
comparing the wound healing abilities of different MSC
sources are still lacking in the literature. On the other
hand, the direct effects of human WJ-MSCs on wound
healing, regeneration and repair still remain unknown. A
new preclinical and clinical research arena investigating
the potential of WJ-MSCs in wounds and wound healing
has just been born and may hold promise for future me-
dical therapies.
Conclusions
Human WJ-MSCs promoted wound healing by para-
crine signaling in our culture conditions in vitro, and in
an in vivo preclinical animal model. If the reported im-
munoprivileged character and safety of WJ-MSCs ob-
served in experimental and first clinical models is further
scientifically proven, WJ-MSCs might represent a feasible,
universal and off-the-shelf technology to enhance normal
wound healing to improve patient survival and quality
of life.Additional files
Additional file 1: Figure S1. Showing flow-cytometry markers and
mesenchymal differentiation of human WJ-MSCs. Flow cytometry analysis
of established human WJ-MSCs (successfully grown on plastic plates)
showing markers used to characterize MSCs (a,b,c,d). Cells were able to
differentiate into osteocytes (e), chondrocytes (f) and adipocytes (g). Images
shown after alizarin red (e), safranin O (f) and oil red (g) staining, respectively.
Additional file 2: Table S1. Showing primer sequences for real-time
PCR. List of SYBR® Green gene primer sequences used in real-time PCR
for the present work. *TGF-β, transforming growth factor-β; CTGF,
connective tissue growth factor; PAI-I, plasminogen activator inhibitor-I;
HIF-1-α, hypoxia inducible factor-1-α; VEGF, vascular endothelial growth
factor; FGF-2, fibroblast growth factor-2.
Additional file 3: Figure S2. Showing WJ-MSC-CM promoted cell
proliferation in an in vivo wound healing model in BALB-c mice. (A) BrdU
staining in the control group. (B) BrdU staining in the treatment group.
(C), (D) Higher magnification (40×) of the above microscopic images were
included for nonconditioned medium-treated (C is magnification of the
marked area in A) and WJ-MSC-CM-treated normal skin fibroblasts (D is
magnification of the marked area in B) to examine in further detail the
Arno et al. Stem Cell Research & Therapy 2014, 5:28 Page 12 of 13
http://stemcellres.com/content/5/1/28increase in cell number or stained nuclei in the WJ-MSC-CM-treated wounds,
compared with controls. Brown nuclei correspond to cells that incorporated
BrdU into their DNA. (Supplemental figure in support of Figure 5).
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